cocaine hydrochloride nasal
NUMBRINO (cocaine hydrochloride nasal) is type. First approved in 2020.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
NUMBRINO is a nasal solution formulation of cocaine hydrochloride approved in 2020 for topical use. It works by reversibly blocking voltage-gated sodium channels in nerve fibers, preventing action potential generation and providing local anesthesia and vasoconstriction. This is a niche specialty pharmaceutical with established clinical utility in specific medical procedures.
NUMBRINO is in peak commercial phase with strong patent protection through 2037, supporting a stable but specialized commercial team focused on procedure-based utilization.
type. Cocaine hydrochloride prevents conduction in nerve fibers by reversibly blocking voltage-gated sodium channels and preventing the transient rise in sodium conductance necessary for generation of an action potential.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NUMBRINO offers career stability in a niche, highly specialized segment with extended patent protection and limited competitive pressure. This role emphasizes deep procedure-based medical knowledge, healthcare system relationships, and regulatory expertise rather than broad market development.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo